Morgan Stanley Talaris Therapeutics, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$2.68 - $3.22 $32,690 - $39,277	-12,198 Reduced 25.21%	36,197 $101,000
Q2 2023 Aug 14, 2023	SELL	$1.78 - $3.2 $402,707 - $723,968	-226,240 Reduced 82.38%	48,395 $147,000
Q1 2023 May 15, 2023	BUY	$1.09 - $2.09 $284,815 - $546,114	261,299 Added 1959.35%	274,635 $516,000
Q4 2022 Feb 14, 2023	SELL	$0.94 - $1.64 $5,501 - $9,598	-5,853 Reduced 30.5%	13,336 $13,000
Q3 2022 Nov 14, 2022	SELL	$2.3 - $5.03 $8,068 - $17,645	-3,508 Reduced 15.46%	19,189 $51,000
Q2 2022 Oct 27, 2022	SELL	$4.51 - $9.85 $51,959 - $113,481	-11,521 Reduced 33.67%	22,697 $103,000
Q2 2022 Aug 15, 2022	SELL	$4.51 - $9.85 $51,959 - $113,481	-11,521 Reduced 33.67%	22,697 $103,000
Q1 2022 Oct 27, 2022	BUY	$6.89 - $16.56 $79,379 - $190,787	11,521 Added 50.76%	34,218 $337,000
Q1 2022 May 13, 2022	BUY	$6.89 - $16.56 $5,133 - $12,337	745 Added 2.23%	34,218 $337,000
Q4 2021 Feb 14, 2022	BUY	$12.18 - $17.0 $117,269 - $163,676	9,628 Added 40.38%	33,473 $511,000
Q3 2021 Nov 15, 2021	BUY	$11.61 - $15.99 $276,840 - $381,281	23,845 New	23,845 $323,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.